Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | LMNA | P02545 | 7/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6863335 | 0.83 | STS (0.56) | MAPTSTSKDM4ETACR1CETP | |
| SCHEMBL22315264 | 0.81 | ALDH1A1 (0.62) | MAPTALDH1A1LMNAKDM4ETSHR | |
| SCHEMBL16577075 | 0.81 | MEN1 (0.62) | MAPTALDH1A1LMNAKDM4ECHRM2 | |
| SCHEMBL6863428 | 0.80 | TACR1 (0.48) | MAPTSTSALDH1A1LMNATACR1 | |
| SCHEMBL1444654 | 0.79 | STS (0.52) | MAPTSTSKDM4ETACR1CETP | |
| SCHEMBL211276 | 0.77 | KCNT1 (0.56) | MAPTALDH1A1LMNAPOLBKDM4E | |
| SCHEMBL8913316 | 0.77 | ALDH1A1 (0.56) | MAPTALDH1A1LMNAKDM4ECETP | |
| SCHEMBL31254088 | 0.77 | ALDH1A1 (0.50) | MAPTALDH1A1LMNAPOLBKDM4E | |
| SCHEMBL31254120 | 0.77 | ALDH1A1 (0.50) | MAPTALDH1A1LMNAPOLBKDM4E | |
| SCHEMBL1574832 | 0.76 | MAPT (0.58) | MAPTSTSTACR1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220603-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220603-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| EP-2473488-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | Zalicus Pharmaceuticals Ltd. (CA) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011026241-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | ZALICUS PHARMACEUTICALS LTD. (CA) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220603-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | CACNA1B, SCN1A, CACNA1I | MAPT 3338/4885STS 1972/4885ALDH1A1 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.